Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA

Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate the efficacy and safety of its novel siRNA asset RBD1016, for the treatment of the rare disease of chronic hepatitis D infection.

Ribocure Pharmaceuticals AB, the international research center of Suzhou Ribo Life Science Ltd, is determined to deliver cutting-edge siRNA therapeutics to patients all over the world. This authorisation marks Ribocure’s and Ribo’s dedication to potentially treat not only HBV infected patients, but also patients infected with HDV. HDV is the most severe form of chronic viral hepatitis, associated with a high risk for developing liver cirrhosis and subsequentially hepatocellular carcinoma.

The hepatitis D virus (HDV) is an RNA virus which requires the presence of hepatitis B virus (HBV) to propagate and cause infection. Globally, HDV affects approximately 5 % of people living with chronic HBV. Hence, it is commonly referred to as a satellite virus because it cannot propagate without the assistance of HBV.

RBD1016 has shown high potency and durability in a Ph1b study in hepatitis B infected patients. In addition, data from nonclinical studies clearly supports that RBD1016 has the potential to optimize the field of HDV treatment by offering a safe and effective alternative to currently available therapies.

“This study clearly marks an advancement of our rare disease portfolio with RNA-based treatment. I am personally impressed by the Ribocure team, in terms of their speed of pushing the program forward from idea to CTA approval, the demonstrated scientific rigor and agility, as well as the highly professional collaborative spirit among the team members.” says Li-ming Gan, CEO Ribocure Pharmaceuticals AB.

Share on social media

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website,
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
Contact information to the Data Protection Officer (DPO):
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal